Compare Realty Income Corp (O) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Realty Income Corp vs Vertex Pharmaceuticals Incorporated — how do they compare? Realty Income Corp trades at $60.35 (market cap $57.74B), while Vertex Pharmaceuticals Incorporated trades at $522.29 (market cap $134.06B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 2.3× Realty Income Corp's market cap, and Realty Income Corp pays a 5.33% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| O | VRTX | |
|---|---|---|
Market Cap | $57.74B | $134.06B |
Sector | Real Estate | Health |
52-Week High | $67.56 | $557.96 |
52-Week Low | $55.93 | $376.62 |
Enterprise Value | $88.37B | $128.18B |
Dividend Yield | 5.33% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Realty Income (O) trades at $61.02, down 0.38% on the day, with a bearish technical signal from moving averages. The stock has missed earnings expectations for the last three quarters, but revenue grew to $5.75B in 2025 with a net income margin of 21.23%. Recent news highlights the company's 136th consecutive monthly dividend increase to $0.2715 per share, underscoring its income-focused appeal amid a 5.3% yield.
The outlook is mixed: analyst consensus leans hold with a $66.50 price target, suggesting modest upside, but rising debt levels and interest rate sensitivity pose risks. Earnings misses and a high P/E of 44.54 indicate valuation concerns, though dividend growth and high occupancy support income stability for long-term investors.
Vertex Pharmaceuticals (VRTX) trades at $528.9, down 3.15% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bullish moving average signal but neutral oscillators, with key support at $522. Fundamentally, 2025 revenue reached $12.0B with a strong net income margin of 35%, though recent quarterly EPS results have been mixed. The company recently completed the acquisition of Crinetics Pharmaceuticals, signaling growth ambitions.
The outlook remains positive given analyst consensus favoring a Buy rating (84%) and a $548.78 price target, implying upside. Key opportunities include revenue growth from new drug launches, while risks involve competitive pressures and earnings volatility. The stock's current valuation at a P/E of 30.8 requires sustained execution to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Realty Income Corp
Realty Income owns roughly 11,400 properties, most of which are freestanding, single-tenant, triple-net-leased retail properties. Its properties are located in 49 states and Puerto Rico and are leased to 250 tenants from 47 industries. Recent acquisitions have added industrial, office, manufacturing, and distribution properties, which make up roughly 17% of revenue.
Read more on O →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
